[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"stage-i-pancreatic-cancer-ajcc-v8\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:stage-i-pancreatic-cancer-ajcc-v8":128},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,41,64,87,109],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100642600",false,"NCT07651358","A Tailored, Web-based Program (COMPASS) to Improve Exercise and Dietary Changes in Stage I-III Pancreatic Cancer Patients Receiving Neoadjuvant Chemotherapy","Community for Physical Activity and Supportive Nutrition Strategies (COMPASS)","Inclusion Criteria:\n\n* Age 18 years or older on date of enrollment\n\n  * Confirmed by review of the date of birth as documented in the electronic medical record (EMR) and subsequently recorded in a case report form (CRF)\n* Diagnosed with stage I-III pancreatic cancer\n\n  * Confirmed by EMR review. In cases where the EMR is unclear, their physician will be contacted and asked to confirm\n* Scheduled to receive neoadjuvant chemotherapy at Oregon Health \\& Science University (OHSU)\n\n  * Confirmed by EMR review. In cases where the EMR is unclear, their physician will be contacted and asked to confirm\n* Willing to adhere to the study protocol\n\n  * Confirmed verbally with the participant and response documented in the Participant Tracking database\n\nExclusion Criteria:\n\n* Cognitive difficulties that preclude answering the survey questions, participating in the intervention, or giving informed consent\n\n  * In the event of a suspected undeclared cognitive impairment, it will be confirmed by physician clearance or professional opinion of the Principal Investigators, Dr. Kerri Winters-Stone and\u002For Dr. Jackilen Shannon\n* A medical condition, movement or neurological disorder, or medication use that contraindicates participation in light intensity exercise\n\n  * Confirmed by a combination of reviewing the EMR, and self-report during the initial screening call. If in the professional opinion of the Principal Investigator, Dr. Kerri Winters-Stone or Dr. Jackilen Shannon, contraindications other than those identified by the patient or physician are present, she may consider the participant ineligible\n* Not fluent in English and therefore incapable of answer survey questions, reading the intervention web portal, and providing informed consent in English\n\n  * Confirmed verbally with the participant and response documented in the Participant Tracking database","ALL","18 Years",{"count":18,"type":19},30,"ESTIMATED","INTERVENTIONAL",[22],"NA","This clinical trial studies whether a tailored, web-based program (web portal), Community for Physical Activity and Supportive Nutrition Strategies (COMPASS), can be used to improve exercise and dietary changes in patients with stage I-III pancreatic cancer who are receiving chemotherapy before surgery (neoadjuvant). Pancreatic cancer is a rare and understudied cancer, particularly in the area of promoting a healthy lifestyle to preserve physical and mental well-being during a long and difficult treatment regimen. Since pancreatic cancer is rare, programs have limited resources available to reach the patients who could benefit from programs aimed at promoting exercise and a healthy diet. The COMPASS web-portal is easily accessed by the patient via a computer, tablet, or phone. It is tailored to the unique needs of pancreatic cancer patients and provides exercise and diet recommendations along with behavioral support as they undergo the long process of cancer therapy. This may be a more effective way to reach and engage with the patient, which may improve exercise and dietary changes in stage I-III pancreatic cancer patients receiving neoadjuvant chemotherapy.",[25,26,27],"Stage I Pancreatic Cancer AJCC v8","Stage II Pancreatic Cancer AJCC v8","Stage III Pancreatic Cancer AJCC v8","RECRUITING","2026-06-12",{"date":31,"type":32},"2026-06-16","ACTUAL",{"date":34,"type":32},"2026-04-15",{"date":36,"type":19},"2027-06-30",{"name":38,"class":39},"OHSU Knight Cancer Institute","OTHER",1,{"id":42,"slug":4,"hasResults":10,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":20,"phases":49,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":40},"100548617","NCT06423326","Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer","A Single-Arm Phase II Clinical Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel as Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma","Inclusion Criteria:\n\n* Histologically or cytologically confirmed - resectable and borderline resectable pancreatic ductal adenocarcinoma\n\n  * Resectability will be defined as per National Comprehensive Cancer Network (NCCN) guidelines using cross-sectional imaging (contrast-enhanced computed tomography or magnetic resonance imaging scans of the abdomen, and pelvis)\n  * Decisions about resectability status will be made in consensus at multidisciplinary meetings\u002Fdiscussions\n\nResectable disease will be defined as:\n\n* No interface of the tumor with celiac artery, common hepatic artery (CHA), or superior mesenteric arteries (SMA) (and, if present, variants)\n* Less than 180° interface between tumor and vessel wall of the portal or superior mesenteric veins (SMV) without vein contour irregularity\n* For tumors of the body and tail of the pancreas, interface with the splenic artery and splenic vein of any degree will be considered resectable disease\n\nBorderline resectable disease will be defined as:\n\n* To include at least one of the following:\n\n  * Tumor abutment \\\u003C 180° of the superior mesenteric artery or celiac axis\n  * Solid tumor contact with CHA without extension to celiac artery (CA) or hepatic artery bifurcation allowing for safe and complete resection and reconstruction\n  * Solid tumor contact with variant arterial anatomy (ex: accessory right hepatic artery, replaced right hepatic artery, replaced CHA, and the origin of replaced or accessory artery)\n  * Tumor induced narrowing of SMV, portal vein (PV) or SMV-PV of \\> 180˚ of the diameter of the vessel\n  * Short segment occlusion of the SMV, PV or SMV-PV with a suitable PV above and SMV below, for reconstruction\n  * Solid tumor contact with inferior vena cava\n  * Biopsy proven N1 disease (regional lymph nodes involved) from pre-referral biopsy or endoscopic ultrasound (EUS)-guided fine needle aspiration (FNA)\n\n    * No distant extrapancreatic disease (M0)\n    * Adults \\> 18 years of age\n    * Able to give informed consent\n    * Able to adhere to study visit schedule and other protocol requirements\n    * Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 1\n    * Absolute neutrophil count (ANC) ≥ 1,500 cells\u002Ful\n    * Platelet count ≥ 100,000 cells\u002Ful\n    * Hemoglobin ≥ 9 g\u002FdL\n    * Serum total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN)\n    * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN\n    * Albumin ≥ 3 g\u002Fdl\n    * Creatinine ≤ 1.5 x ULN\n    * Male, or a non-pregnant and non-lactating female\n    * Women of child-bearing potential - defined as a sexually mature woman who has not undergone hysterectomy - the surgical removal of the uterus or bilateral oophorectomy - the surgical removal of both ovaries or has not been naturally postmenopausal for at least 24 consecutive months, i.e., has had menses at any time during the preceding 24 consecutive months, must commit to true abstinence from heterosexual contact, or agree to use, and be able to comply with, effective contraception without interruption for 28 days prior to starting gemcitabine\u002Fcisplatin\u002Fnab- paclitaxel (including dose interruptions) until treatment with gemcitabine\u002Fcisplatin\u002Fnab-paclitaxel is complete\n    * Male subjects must practice true abstinence or agree to use a condom during sexual contact with a female of childbearing potential or a pregnant female while on treatment (including during dose interruptions) with gemcitabine\u002Fcisplatin\u002Fnab-paclitaxel and for 6 months following gemcitabine\u002Fcisplatin\u002Fnab- paclitaxel discontinuation, even if he has undergone a successful vasectomy\n\nExclusion Criteria:\n\n* Peripheral neuropathy of grade 2 or greater by Common Terminology Criteria for Adverse Events (CTCAE) 4.0. In CTCAE version 4.0 grade 2 sensory neuropathy is defined as \"moderate symptoms; limiting instrumental activities of daily living (ADLs)\"\n* Concurrent severe and\u002For uncontrolled medical conditions which could compromise participation in the study such as unstable angina, myocardial infarction within 6 months, unstable symptomatic arrhythmia, symptomatic congestive heart failure, uncontrolled diabetes, serious active, uncontrolled infection after inadequate biliary drainage if tumor obstructing bile duct, or psychiatric illness\u002Fsocial situations\n* Pregnancy (positive pregnancy test) or lactation\n* Known central nervous system (CNS) disease, except for treated brain metastasis. Treated brain metastases are defined as having no evidence of progression or hemorrhage after treatment and no ongoing requirement for dexamethasone, as ascertained by clinical examination and brain imaging (MRI or CT) during the screening period. Anticonvulsants (stable dose) are allowed. Treatment for brain metastases may include whole brain radiotherapy (WBRT), radiosurgery (radiosurgery \\[RS\\]; Gamma Knife, linear accelerator \\[LINAC\\], or equivalent) or a combination as deemed appropriate by the treating physician. Patients with CNS metastases treated by neurosurgical resection or brain biopsy performed within 3 months prior to day 1 will be excluded\n* Previous (within the past 5 years) or concurrent presence of other untreated cancer, except nonmelanoma skin cancer and in situ carcinomas\n* History of allergy or hypersensitivity to any of the study drugs\n* Current abuse of alcohol or illicit drugs\n* Inability or unwillingness to sign the informed consent form",{"count":48,"type":19},36,[50],"PHASE2","This phase II trial tests how well gemcitabine, cisplatin and nab-paclitaxel given before surgery (neoadjuvant) works in treating patients with pancreatic cancer that can be removed by surgery (resectable) or that is borderline resectable. The standard treatment for resectable and borderline resectable pancreatic cancer is a combination of surgery and chemotherapy. Neoadjuvant therapy is more feasible and could improve outcomes compared to patients receiving surgery first. Gemcitabine is a chemotherapy drug that blocks the cells from making DNA and may kill tumor cells. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Nab-paclitaxel is an albumin-stabilized nanoparticle formulation of paclitaxel, an antimicrotubule agent that stops tumor cells from growing and dividing and may kill them. Nab-paclitaxel may have fewer side effects and work better than other forms of paclitaxel. Gemcitabine, cisplatin and nab-paclitaxel may be an effective neoadjuvant treatment option for patients with resectable or borderline resectable pancreatic cancer.",[53,54,25,26,27],"Borderline Resectable Pancreatic Ductal Adenocarcinoma","Resectable Pancreatic Adenocarcinoma","2026-04-17",{"date":57,"type":32},"2026-04-22",{"date":59,"type":32},"2024-08-06",{"date":61,"type":19},"2027-12-31",{"name":63,"class":39},"Emory University",{"id":65,"slug":4,"hasResults":10,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":4,"eligibilityCriteria":69,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":70,"targetDuration":4,"studyType":20,"phases":72,"briefSummary":73,"conditions":74,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":40},"100602522","NCT07124611","A Brief Psychological Intervention to Improve Emotional Well-Being During Neoadjuvant Therapy for Pancreatic Cancer","Testing the Feasibility of Incorporating Psychosocial Oncology During Neoadjuvant Therapy for Patients With Pancreatic Cancer","Inclusion Criteria:\n\n* Adults ≥ 18 years of age\n* Patient:\n\n  * Newly diagnosed patients with localized pancreatic ductal adenocarcinoma (PDAC) presenting to Ohio State University Wexner Medical Center-Comprehensive Cancer Center (OSUMC-CCC)\n  * Plans to initiate neoadjuvant therapy prior to surgical resection\n  * Neoadjuvant therapy (NT) and\u002For surgery may occur at another facility\n\nExclusion Criteria:\n\n* Prisoners\n* Persons unable to provide consent\n* Patients unlikely to undergo surgical resection following NT based on anatomical or performance status considerations\n* Confirmed or presumed metastatic disease\n* Already received ≥ 2 cycles of chemotherapy",{"count":71,"type":19},60,[22],"This clinical trial tests how well a psychosocial oncology intervention during neoadjuvant therapy works for patients with pancreatic cancer that has not spread to other parts of the body (localized). Chemotherapy and\u002For radiation therapy is often recommended prior to surgeryf or patients with pancreatic cancer; this is known as neoadjuvant therapy (NT). The primary advantages of NT include: reducing the size of the cancer mass and\u002For reducing the spread of cancer, to improve the likelihood of getting all the cancer during surgery, and because receiving chemotherapy after pancreas surgery can be challenging. Other research has shown that NT can lead to improved survival and a lower rate of the cancer returning. Despite these positive effects, NT can be associated with significant physical and emotional side effects. To prepare patients for future surgery and maintain health during chemotherapy and\u002For radiation, prehabilitation is often recommended. This can include nutritional and physical therapy to help with physical health. An oncology (cancer) psychosocial intervention during NT may be feasible and helpful to patients with localized pancreatic cancer.",[75,76,25,77],"Localized Pancreatic Ductal Adenocarcinoma","Stage 0 Pancreatic Cancer AJCC v8","Stage IIA Pancreatic Cancer AJCC v8","2026-02-17",{"date":80,"type":32},"2026-02-19",{"date":82,"type":32},"2025-12-22",{"date":84,"type":19},"2026-12-31",{"name":86,"class":39},"Ohio State University Comprehensive Cancer Center",{"id":88,"slug":4,"hasResults":10,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":4,"eligibilityCriteria":92,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":93,"targetDuration":4,"studyType":20,"phases":95,"briefSummary":96,"conditions":97,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":40},"100479124","NCT05518903","Investigational Scan (68Ga-FAPI-46 PET\u002FCT) for Imaging of Cancer-Associated Fibroblasts for Localized Pancreatic Ductal Adenocarcinoma","Quantitative In Vivo 68Ga-Fibroblast-Activation-Protein-Inhibitors (FAPI)-46 PET Imaging of Cancer-Associated Fibroblasts (CAFs) in Pancreatic Ductal Adenocarcinoma (PDA)","Inclusion Criteria:\n\n* Adults \\> 18 years (yrs.) with treatment-naive biopsy-proven PDA or with findings diagnostic for PDA on baseline imaging (CT, MRI, or PET)\n* Localized disease expected to undergo surgical resection following neoadjuvant therapy (NAT)\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* Hypersensitivity to any excipients in 68Ga-FAPI-46\n* Require emergency surgery\n* Non-PDA histology on biopsy\n* Histopathologically proven metastatic PDA\n* Pregnant or lactating women",{"count":94,"type":19},130,[50],"This phase II trial tests whether 68Ga-FAPI-46 positron emission tomography (PET)\u002Fcomputed tomography (CT) scan works to image cancer-associated fibroblasts (CAFs) in patients with pancreatic ductal adenocarcinoma (PDA) that has not spread to other parts of the body (localized). CAFs are a type of connective tissue cell that are found within or near cancerous tissue. Many CAFs express a protein called fibroblast activation protein (FAP) that are not found on healthy cells in large amounts. 68Ga-FAPI-46 is a radioactive chemical compound designed to circulate through the body and attach itself to FAP on PDA cells. A PET\u002FCT scan is then used to detect the location of FAP lesions. PET scan is a procedure in which a small amount of radioactive glucose (sugar) is injected into a vein, and a scanner is used to make detailed, computerized pictures of areas inside the body where the glucose is taken up. Because cancer cells often take up more glucose than normal cells, the pictures can be used to find cancer cells in the body. CT scan is a procedure that uses a computer linked to an x-ray machine to make a series of detailed pictures of areas inside the body. The pictures are taken from different angles and are used to create 3-dimensional (3-D) views of tissues and organs. Combining a PET scan with a CT scan can help make the image easier to interpret. PET\u002FCT scans are hybrid scanners that combine both modalities into a single scan during the same examination. Giving 68Ga-FAPI-46 PET\u002FCT may help doctors improve upon the diagnosis and management of PDA.",[98,99,76,25,77],"Localized Pancreatic Adenocarcinoma","Resectable Pancreatic Ductal Adenocarcinoma","2025-09-29",{"date":102,"type":32},"2025-10-02",{"date":104,"type":32},"2022-11-15",{"date":106,"type":19},"2028-06-30",{"name":108,"class":39},"Mayo Clinic",{"id":110,"slug":4,"hasResults":10,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":115,"targetDuration":4,"studyType":117,"phases":4,"briefSummary":118,"conditions":119,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":40},"100561822","NCT06595160","Determining the Link Between Dietary Patterns, Fecal Microbiome and Response to Neoadjuvant Chemotherapy","Determining the Link Between Dietary Patterns, Fecal Microbiome and Response to Neoadjuvant Chemotherapy in Pancreatic Ductal Adenocarcinoma Patients","Inclusion Criteria:\n\n* \\* Age ≥ 18 years with signed informed consent form\n\n  * Patients must have a histological diagnosis of PDAC\n  * Resectable or borderline resectable PDAC on imaging\n\nExclusion Criteria:\n\n* \\* Patients with locally advanced and metastatic stage IV PDAC\n\n  * Patients who have already received or completed neoadjuvant chemotherapy for PDAC\n  * Patients with active malignancy receiving systemic therapy",{"count":116,"type":19},87,"OBSERVATIONAL","This study explores the relationship between pre-treatment dietary patterns, fecal microbiome, and response to chemotherapy in patients with pancreatic ductal adenocarcinoma.",[53,99,25],"2025-07-30",{"date":122,"type":32},"2025-08-01",{"date":124,"type":32},"2024-08-05",{"date":126,"type":19},"2027-08-07",{"name":63,"class":39},""]